First Tracks Biotherapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Feb 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 15, 2027The maintenance fee for Humanized Antibodies Directed Against Complement Protein C5 (US 9,133,269) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due Aug 16, 2027The maintenance fee for Methods of Generating Libraries and Uses Thereof (US 9,260,533) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Antibodies Directed Against IL-17 (US 9,328,166) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
- Sep 22 US 12,742,010 PD-1 Agonist and Method of Using Same
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,685,897 | Methods of Generating Libraries and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,260,533 | Methods of Generating Libraries and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,637,556 | Methods of Generating Libraries and Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,603,950 | Methods of Generating Libraries and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,328,166 | Antibodies Directed Against IL-17 In force · High confidence | In force | High confidence | |
| US 8,926,978 | Antibodies Directed Against Nerve Growth Factor (NGF) In force · High confidence | In force | High confidence | |
| US 9,951,126 | Antibodies Directed Against Nerve Growth Factor (NGF) In force · High confidence | In force | High confidence | |
| US 9,133,269 | Humanized Antibodies Directed Against Complement Protein C5 In force · High confidence | In force | High confidence | |
| US 10,059,764 | Antibodies Directed Against INTERLEUKIN-33 (IL-33) and Methods of Making and Using In force · High confidence | In force | High confidence | |
| US 10,836,820 | Method of Treating Inflammatory Disorder with Antibodies Directed Against INTERLEUKIN-33 (IL-33) In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.